Management of High LDL Cholesterol with Pravastatin

Introduction to Pravastatin Therapy

The American College of Cardiology recommends pravastatin 40 mg daily as an acceptable treatment option for patients with high LDL cholesterol, reducing LDL-C by approximately 34% and lowering major coronary events by 19-24% 1

Pravastatin 40 mg daily reduces LDL-C by approximately 34%, which would lower a patient's LDL from 200 mg/dL to approximately 132 mg/dL, representing moderate-intensity statin therapy according to current guidelines 1, 5
In clinical trials, pravastatin 40 mg achieved median LDL-C levels of 95 mg/dL in post-ACS patients and reduced LDL to near 100 mg/dL in patients with established CHD 2, 3, 4

The PROVE-IT trial showed that atorvastatin 80 mg achieved LDL-C of 62 mg/dL versus pravastatin 40 mg achieving 95 mg/dL, representing a 33 mg/dL (35%) difference, and translating to a 16% reduction in composite cardiovascular endpoints 2, 3, 4, 5
Atorvastatin 10 mg reduces LDL-C by approximately 43-50%, significantly more than pravastatin 40 mg 1

Pravastatin has an excellent safety profile with no cases of severe myopathy (rhabdomyolysis) observed in major clinical trials, and a lower rate of transaminase elevations (1.1%) compared to high-dose atorvastatin (3.3%) 1, 2, 3, 4
Pravastatin can be used without dose adjustment with multiple medications, including amiodarone, ranolazine, and warfarin, but requires dose limitation to 40 mg when used with cyclosporine, tacrolimus, everolimus, or sirolimus 1

The American Heart Association recommends determining the patient's cardiovascular risk category to guide LDL-C goal setting, with <70 mg/dL for very high-risk, <100 mg/dL for high-risk, and <130 mg/dL for moderate-risk patients 2, 5
The American College of Cardiology suggests that each 10% reduction in LDL-C reduces stroke risk by approximately 15.6% 6